Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 134Carcinoma, Non-Small-Cell Lung 133Prostatic Neoplasms 87Lung Neoplasms 43Neoplasms 31Squamous Cell Carcinoma of Head and Neck 30Neoplasm Metastasis 30Stomach Neoplasms 26Head and Neck Neoplasms 24Esophageal Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 17Pancreatic Neoplasms 17Ovarian Neoplasms 16Urinary Bladder Neoplasms 13Sarcoma 12Adenocarcinoma of Lung 9Triple Negative Breast Neoplasms 8Fallopian Tube Neoplasms 8Carcinoma, Transitional Cell 8Carcinoma, Ovarian Epithelial 8Adenocarcinoma Of Esophagus 7Recurrence 6Carcinoma 6Inflammatory Breast Neoplasms 5Carcinoma, Squamous Cell 5Breast Neoplasms, Male 5Adenocarcinoma, Bronchiolo-Alveolar 5Adenocarcinoma 5Laryngeal Neoplasms 4Esophageal Squamous Cell Carcinoma 4

Interventions

Sunitinib 2Paclitaxel 2valrubicin 1temsirolimus 1sipuleucel-T 1luprolide acetate gel depot 1ferumoxtran-10 1abiraterone 1abemaciclib 1Suspensions 1Surveys and Questionnaires 1Standard of Care 1Radiotherapy 1Prednisone 1Prednisolone 1Powders 1Pemetrexed 1Neoadjuvant Therapy 1National Cancer Institute (U.S.) 1Mitomycin 1Magnetic Resonance Spectroscopy 1Leuprolide 1Fatty Acids, Omega-3 1Educational Status 1Docetaxel 1Bevacizumab 1Atorvastatin 1Administration, Intravesical 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urogenital Neoplasms × Docetaxel × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔